Vitamin A (VA) is essential for fetal lung development and postnatal lung maturation. VA is stored mainly as retinyl esters (RE), which may be mobilized for production of retinoic acid (RA). The current study was designed to 1) evaluate several acidic retinoids for their potential to increase RE in the lungs of VA-supplemented neonatal rats, and 2) determine the expression of retinoid homeostatic genes related to retinol uptake, esterification and catabolism as possible mechanisms. When neonatal rats were treated with VA combined with any one of several acidic retinoids (RA, 9-cis-RA, or Am580, a stable analog of RA), lung RE increased ~5-7-times more than after an equal amount of VA alone. Retinol uptake and esterification during the period of absorption correlated with increased expression of both STRA6 (retinol-binding protein receptor) and LRAT (retinol esterification), while a reduction in RE after 12 hours in Am580-treated, VA-supplemented rats correlated with a strong and persistent increase in CYP26B1 (RA hydroxylase). We conclude that neonatal lung RE can be increased synergistically by VA combined with both natural and synthetic acidic retinoids, concomitant with induction of the dyad of STRA6 and LRAT. However, the pronounced and prolonged induction of CYP26B1 by Am580 may counteract lung RE accumulation after the absorption process is completed.
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INTRODUCTION
Vitamin A (VA) is an essential micronutrient that is required for fetal lung development and alveolar septation in the postnatal period (1) (2) (3) . The active metabolite of VA, retinoic acid (RA), fulfills nearly all of the functions of VA, but unlike VA which is stored in tissues as retinyl ester (RE) and mobilized to produce RA (4) , no significant amount of RA is stored and the pool of RA turns over rapidly (5) . RA and other retinoids have been shown to enhance alveolar septation in neonatal rats and mice [reviewed in (2, 3, 6, 7) ], and in some cases to improve lung repair after injury in adults (3, 8, 9) . Most of the VA present in the lungs is in the form of RE (10) (11) (12) . In full term infants, a process of significant RE accumulation in the lungs has begun from the third trimester of fetal life, after which the stored RE becomes quickly depleted during late gestation and early postnatal life (10) . By contrast, preterm infants often have low VA status at birth (13) (14) (15) , which may contribute to poor lung maturation and increased susceptibility to respiratory diseases (16) . Therefore, ways to improve RE storage in the lungs in the postnatal period could be useful clinically for supporting retinoid-requiring metabolic functions and aiding postnatal lung development.
Previously we have tested a combination of VA (retinol) and RA, referred to as VARA [10:1 molar mixture of VA and RA] as an oral supplement for promoting lung RE formation (12) .
Lung RE increased synergistically, at least 4-fold more than for an equal amount of VA alone (17). As RA is not reduced to retinol in vivo and thus is not a substrate for tissue RE synthesis, the increase in RE in the lungs implies that RA plays a regulatory role in this organ, in some 4 manner facilitating RE formation. The synergistic effect of VARA was selective for the lungs, as RE formation in the liver did not differ between VARA and an equal dose of VA only (12, 17) .
In a metabolic study using [ 3 H]-retinol to trace the uptake of newly absorbed retinol, we found that RA served to direct more of the [ 3 H]-retinol tracer, and thus of the oral VA supplement, into the neonatal lung (12) . The inclusion of RA in the diet of adult rats also increased retinol uptake kinetics into the lung (18). However, the mechanisms involved in the VARA synergy are still unknown.
Of the many genes that are regulated in vivo by RA, several play prominent roles in retinoid homeostasis (19). Lecithin:retinol acyltransferase (LRAT) and RA hydroxylases of the CYP26 family of cytochrome P450 genes, which catalyze the esterification of retinol and the oxidation of RA, respectively, are known to be regulated by RA in certain tissues (20) . The expression of these enzymes varies with VA status and appears to provide a level of control over VA metabolism (20) . During VA sufficiency, the continued presence of RA, a signal of high VA status, maintains the expression of LRAT (20). CYP26A1 and CYP26B1 also increase in some tissues when the concentration of RA rises (21). Conversely, in the situation of VA deficiency, when the concentration of RA is very low, LRAT is down-regulated (22), and CYP26 is maintained at a very low level (23, 24) . Therefore, to a certain extent, the self-regulatory mechanisms involving RA render the body able to modulate its retinol metabolism and thus to avoid both VA deficiency and toxicity. Another protein that may contribute to retinoid homeostasis is Stra6 (stimulated by retinoic acid gene 6), a transmembrane receptor for 5 retinol-binding protein, RBP, and mediator of retinol uptake from plasma and extracellular fluid into cells (25) . Stra6 is expressed at high levels in the retina and at lower levels in a variety of embryonic and adult cells or organs (26) , including adult lung tissue (27) . But whether the Stra6 gene is expressed in the neonatal lung and involved in VA uptake in the postnatal period is still unclear.
In the present study, we first determined whether acidic retinoids besides all-trans-RA can produce the "VARA synergy." We then tested the hypothesis that RA and Am580, a retinobenzoic acid analog of RA, which is known both for its resistance to metabolism and its selective activation of the nuclear receptor RAR-α (28, 29) , can acutely alter neonatal lung 7
Tissue collection
At designated times, pups were killed with carbon dioxide. Heparinized blood was collected from the vena cava or heart for preparation of plasma and the lungs and liver were removed, trimmed, weighed, and frozen immediately in liquid nitrogen.
Retinoid Analysis
Tissue lipids were extracted by the procedure of Folch et al. (30) . Portion of the extracts underwent an alkaline hydrolysis to convert RE to retinol and, after addition of a known amount of an internal standard, trimethylmethoxyphenyl-(TMMP)-retinol, samples in 100 µl of methanol were subjected to analysis by reverse-phase HPLC (31), monitored by a Waters (Waters Corp., Milford, MA) 960 photodiode array detector. The areas of the peaks for TMMP-retinol and retinol were analyzed by Millenium-32 (Waters) software and tissue total retinol concentrations were calculated. For some samples, the concentration of tissue RE was determined without saponification (31) . Because RE constituted >90% of total retinol for each treatment group, we have referred to total retinol as RE in the figures and text, unless otherwise indicated.
Analysis of [ 3 H]-retinol metabolism
Extracts of lung and liver total lipids, prepared as described above, were evaporated and subjected to liquid scintillation spectrometry to determine the total 3 H (percent of dose) in the lungs and liver 12 hours after dosing. Another portion of the organic solvent extract was dried, 
Gene mRNA level determination
Total RNA from the lungs of individual pups was extracted using a guanidine extraction method and complementary DNA (cDNA) was prepared using reverse transcriptase (33 
Statistical Analysis
Data are presented as the group mean ± SE. Depending on the experiment, differences were tested by one-factor ANOVA or two-factor ANOVA followed by Fisher's protected least significant difference test, and least squares means test. When variances were unequal, data were transformed to log10 values before statistic analysis. Differences with P < 0.05 were considered significant.
RESULTS
All-trans-RA and 9-cis-RA and both combined each promote RE formation
All-trans-RA is considered the major form of RA with endogenous activity as a ligand for nuclear receptors of the RAR family (RAR-α, RAR-ß, and RAR-γ) (34). Although the status of 9-cis-RA as an endogenously produced retinoid is uncertain, it is known as an effective activator for receptors of the RXR family, when added exogenously. In some situations, both ligands in combination promote gene transactivation. Therefore we first determined the response of the neonatal rat lung to treatments with all-trans-RA, 9-cis-RA, and a 1:1 combination of both isomers, administered in the absence of VA or combined with a supplement of VA (molar ratio of 10 VA: 1 acidic retinoid). Treatments were given daily on postnatal days 5, 6 and 7 and lung and plasma retinol were determined on day 8. Fig. 1A shows that RA produced a small increase in lung RE when given alone, as we have shown previously (12) , indicating that RA influences the metabolism of endogenous retinol in the absence of VA supplementation. When RA was 10 combined with VA as VARA, lung RE increased ~7 times higher as compared to treatment with VA alone. In contrast to all-trans-RA, 9-cis-RA in the absence of VA had no effect on lung RE, suggesting this isomer does not significantly regulate the metabolism of endogenous retinol in the lungs. However, similar to all-trans-RA, 9-cis-RA produced a significant although slightly lower synergy when given with VA. The combination of at-RA and 9-cis-RA (mixed 1:1, with total RA equal to that given as either isomer alone), had no additional effect.
The concentration of plasma retinol (Fig. 1B) was within the normal range for neonates in all treatment groups. Plasma retinol levels were ~30% higher for each treatment that included VA, regardless of whether an acidic retinoid was co-administered (all P<0.05), whereas none of the acidic retinoids alone had a significant effect. Therefore, plasma retinol responded only to the VA component of the dose.
From this initial study we confirmed that at-RA is able to provide a significant "boost" to VA (e.g., as VARA), by increasing lung RE content ~5-7 times. To further test the interaction of VA and acidic retinoids on lung RE formation and to examine regulatory processes, we next compared all-trans-RA, as the predominant natural regulatory isomer, and a retinobenzoic acid analog of RA, Am580, which has been shown to relatively resistant to metabolism and to bind selectively to the RAR-α form of nuclear retinoid receptors (29) . All-trans-RA and Am580, with and without VA, were studied their ability to promote lung RE formation, enhance the uptake of newly absorbed retinol, and alter the expression of genes potentially important for retinol uptake, esterification, and homeostasis.
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VA combined with RA or Am580 increases lung RE significantly at 6 hours and 12 hours
We conducted two studies, one of 6 hours and one of 12 hours duration, each with groups of 6-7-day old neonates that were treated orally with oil (control), VA alone, RA alone, VARA, Am580 alone, and VAAm. The values for the control groups in the two experiments were very similar and thus treatment responses for both experiments are presented together for comparison.
Lung RE increased after VA supplementation alone which was evident as early as 6 hours after dosing ( Fig. 2A) . Notably, the magnitude of increase was the same at both 6 and 12 hours ( Fig. 2B ) for the VA, RA, and VARA groups, implying that the uptake of VA and its storage as RE in the lungs is very rapid after oral dosing, reaching a steady state by 6 hours. Am580 alone produced a small increase in lung RE at both times ( Fig. 2A, B) . Thus, Am580, like RA, influences the metabolism of endogenous retinol. However, whereas the synergy with VAAm was significant at both 6 and 12 hours, lung RE in the VAAm group was signifcantly lower at 12 hours than at 6 hours, and lower for the VAAm group than for the VARA group at 12 hours.
These results indicated that the stable analog Am580 is as effective as RA for promoting RE formation in the very early absorptive period (6 hours), while Am580 appeared to have the effect of quickening retinol metablism in the lung, as evidenced by the fall in lung RE in the post-absorptive period, measured at 12 hours.
RA and Am580 promote higher lung uptake of newly absorbed 3 H-retinol
In the 12-hour study, we included a tracer of However, the uptake of [ 3 H]-retinol was significantly higher in the lungs of neonates treated with at-RA, VARA, Am580, and VAAm (all P < 0.05 versus control). From these results it can be inferred that VA itself did not affect the uptake of newly absorbed retinol, whereas both at-RA and Am580 promoted a higher uptake of newly absorbed retinol, whether or not the mass of VA being absorbed at the time was low, i.e., without VA, or high, after the VA supplement. We noted, however, that more 3 H was present in the lungs of noenates treated with VARA group than with VAAm. This result might be due to a difference in the rate of retinol metabolism as affected by at-RA and Am580.
We also measured the uptake of the orally administered [ 3 H]-retinol into the liver, the major storage organ for VA, for comparison to lung. The percentage of [ 3 H]-retinol taken up by the liver was higher, as expected; however, in addition, we noted that the treatment effect in liver 13 differed from that in lung. In the liver, [ 3 H]-RE was increased only by VA and VARA (Fig. 3B ).
We did not expect VARA to increase the mass of liver RE more than VA alone, because the VARA synergy has not been observed for liver (12, 17) . Similarly, VAAm did not increase liver RE content more than VA alone. However, liver from the VAAm-treated group did not show the same increase in [ 3 H-retinol as in the VA and the VARA groups. We surmised this might be due to a higher rate of retinol metabolism in the VAAm group. The difference between VARA and
VAAm did not appear to be due to a difference in the fractional conversion of newly absorbed retinol to RE, as the percentage of 3 H present as [ 3 H]-RE was similar in the VARA and VAAm groups (data not shown).
The expression of retinoid homeostatic genes is differentially regulated in neonatal lung by
at-RA and Am580
The rapid effect of VARA and VAAm on retinol uptake and RE accumulation in the lungs suggested that if changes in gene expression are responsible, they must occur early after treatment. We thus determined the expression of several genes implicated in retinoid homeostasis, in the lungs of neonates in the 6 hour and 12 hour studies. Gene expression was determined by quantitative PCR for STRA6, LRAT, and two members of the CYP26 family, CYP26A1 and CYP26B1, as well as the cellular retinol-binding protein, CRBP1.
Results for STRA6, a transmembrane protein receptor for RBP which facilitates the uptake of retinol into cells(25), showed that both RA and Am580 induced expression to a level 3~4 times 14 higher than the control group (Fig. 4) . VA alone had no significant effect, while it slightly attenuated the induction of STRA6 by the acidic retinoids. The elevated level of STRA6 mRNA at 6 hours suggests that an increase in retinol uptake from the extracellular RBP-retinol complex into the neonatal lungs via the STRA6 receptor could be a mechanism for the rapid response of the neonatal lungs to acidic retinoids. Interestingly, STRA6 expression at 12 hours was lower than at 6 hours for all but the control group, and no longer differentially affected by the retinoid treatments. These results indicate that STRA6 expression is very dynamically regulated, and suggest that STRA6 could play a more significant role in the uptake of retinol into the lungs especially during the postprandial period of maximal retinol absorption.
Because LRAT, CYP26B1 and CYP26A1 are important genes in VA homeostasis, and they are known to be regulated by RA in tissue-specific patterns (20, 21), we next evaluated their expression in both the 6-hour and the 12-hour studies. LRAT expression was increased at 6 hours by all treatments, in the order VA < at-RA = VARA << Am580 and VAAm580 (Fig. 5) . By 12 hours, LRAT mRNA was reduced towards basal levels in the VA group and had fallen entirely to or somewhat below basal levels in the lungs of RA and VARA-treated neonates. By comparison with RA, Am580 dramatically increased LRAT mRNA at 6 hours and maintained this level at 12 hours. The expression of CRBP1, a retinol chaperone that delivers retinol to LRAT, was readily detectable in neonatal lung, as reported by others (35) but its expression did not differ significantly with treatment (data not shown).
CYP26A1 expression did not increase in neonatal lung in response to VA or at-RA, but was 15 up-regulated ~2-fold by VARA, and 4-5-fold by Am580 at 6 hours (Fig. 6 ). CYP26A1 was lower at 12 hours compared to 6 hours for all treatments. By 12 hours, the VA, RA, and VARA groups did not differ from the control group. Although the expression of CYP26A1 was lower at 12 hours than at 6 hours in the Am580-and VAAm-treated groups, CYP26A1 was still significantly elevated in the lungs of neonates that received these treatments, compared to all other groups.
By contrast to CYP26A1, CYP26B1 exhibited much stronger induction (Fig. 7) . The level of CYP26B1 mRNA was elevated 4-5-fold by all of the treatments, compared to control, at 6
hours. Moreover, Am580 further and dramatically increased CYP26B1 mRNA at 12 hours, whether given alone or as VAAm, reaching levels 16-17-times higher than the control group.
Since CYP26B1 expression was higher and more responsive to retinoids compared to CYP26A1, CYP26B1 might play the major role in metabolizing RA in neonatal lungs. Our previous research had indicated that VA given orally in combination with at-RA (VARA) increased retinol uptake and lung RE formation much more effectively compared with VA given individually (12, 17) . For reference, the VA dose we have used in our studies of neonatal rats, described in more detail in (12) , is representative of the 50,000 IU (15 mg) dose of retinol that has been administered to human newborns in studies which have shown reduced mortality in the first year of life (47, 48) . The dose of RA we have used is similar to that first shown by Massaro and Massaro (49) to improve alveolar septation in postnatal rats. We have previously shown by conducting a dose-dilution study that VARA has about 4-5 times the effect of the standard dose of VA alone (17). In the present study, the synergy between VA and at-RA or VA and Am580 18 was as great or greater, with a 5-7-fold increase in lung RE content just 6h after treatment with VARA or VAAm (Fig. 2) . The administration of RA redirects part of the flow of supplemental VA in the neonate lungs, as supported by increased [ 3 H]-retinol uptake in RA or Am580-treated neonates (Fig. 3) . This result also agrees with the results of a long-term feeding study in adult rats fed an RA-supplemented diet, in which the rates of retinol uptake into the lungs were increased, compared to control rats (18).
DISCUSSION
In this study, we examined the expression of LRAT, CYP26A1 and CYP26B1, and STRA6
because we hypothesized they could play a major role in redirecting the flow of VA into the lungs, as well as influencing the turnover of RA. As LRAT functions to esterify retinol to its storage form, RE, while CYP26A1 and CYP26B1 oxidize RA to inactive polar metabolites (21), these genes could significantly affect RE levels in RA-responsive tissues. STRA6 was of interest because in studies of the retina and retinal pigment epithelial cells, STRA6 and LRAT cooperatively enhanced the uptake and accumulation of retinol as RE (25). STRA6 mRNA was shown by Northern blot to be present at relatively low abundance in adult lung tissue (25).
Mutations in STRA6 have been associated with development defects including lung hypoplasia (27) , but the physiological regulation of STRA6 in the lung has not been reported. Indeed, prior demonstrations of STRA6 regulation by RA have been in cancer cells, originally in P19 embryonal carcinoma cells (50), and we believe our results may be the first evidence of the physiological regulation of STRA6 by RA coupled with increased retinol uptake in normal tissue.
Our comparison of the expression of STRA6, LRAT, and CYP26A1 and CYP26B1 provides 19 insight into the treatment-initiated changes in expression in the period of most active VA absorption (6 h), as well as in the period after absorption has been completed and tissue retinoid turnover and homeostatic regulation may be observed (12 hours). Since all-trans-RA can be rapidly metabolized by the 4-hydroxylase activity of CYP26A1 and CYP26B1 (21), while the methyl groups at C-4 of Am580 prevent oxidation, the use of Am580 in our studies allowed us to ask whether a more persistent retinoid might extend or exaggerate the effects observed for at-RA on lung VA metabolism.
VARA and VAAm did not differ from each other with respect to lung RE and STRA6
expression at 6 h. For STRA6, the increase in mRNA was transient and coincided with the time when the uptake of newly absorbed retinol from the oral VA supplement would be most active (Fig. 4) . As illustrated in summary Fig. 8 , STRA6 may therefore contribute to retinol uptake in the absorptive period (6 hours), provided that sufficient VA is present (Fig. 8A for RA, 8C for Am580). However, by 12 hours after dose administration, the input of VA and the level of STRA6 had both declined (Fig. 8B for RA, 8D for Am580), and thus the process of retinol uptake would no longer be likely to contribute to the VARA synergy. As the lung RE content is the result of integrated, cummulative changes over time, where gene expression has been measured at discrete times, it is possible that the reduction in lung RE in the VAAm group at 12
hours results from a change in balance of several factors.
For LRAT, lung LRAT mRNA levels changed signficantly with both time and treatment.
Previous studies have showed that LRAT mRNA and LRAT enzymatic activity are closely 20 correlated (33, 51), and thus the higher expression of LRAT mRNA at 6 hours in all groups ( Fig.   5 and Fig. 8A,C) , coupled with the increased lung RE content in the VARA and VAAm groups, suggests that retinol substrate was the limiting factor in the VARA-and VAAm-treated neonates, while LRAT may have been the limiting factor in the neonates treated only with VA. At 12 hours, LRAT expression had fallen to near basal levels in the RA and VARA groups, but remained high in the Am580 and VAAm groups ( Fig. 5 and summary Fig, 8B,D) . This result suggests that if a second supplement of VA were given around 12 hours after treatment with Am580 or VAAm, it might synergize with the previously administered Am580 to further elevate lung RE, because LRAT expression was already highly induced. We observed, however, that treatment with VAAm resulted in a lower lung RE concentration at 12 hours compared with either VARA at 12
hours or VAAm at 6 hours ( Fig. 2A ,B and summary Fig. 8B,D) . The pattern of expression for CYP26B1 in particular appears to explain these differences, as Am580 further upregulated the expression of CYP26B1 at 12 hours (Fig. 6 ). The high levels of both LRAT and CYP26B1
induced by Am580, especially dramatically for CYP26B1, could speed up the rate of metabolism of retinol and change the balance of the metabolic pathway toward the direction of retinoid oxidation. Although the substrate for CYP26A1 and CYP26B1 is usually considered to be at-RA, it is possible that one or both of these enzymes also oxidizes retinol, because 4-hydroxy-and 4-oxo-retinol have been found as an endogenous metabolite in vivo (52-54), which increased in plasma after VA supplementation (55) . We therefore speculate that the oxidative metabolism of retinol itself could have been increased in the lungs of the neonates treated with Am580 or VAAm, which may account for the reduction in RE mass at 12 hours in the VAAm group, as 21 compared both to the VARA group at 12 hours and the VAAm group at 6 hours (Fig. 8D) .
Although CYP26A1 was also up-regulated by Am580, it did not increase in response to RA and there was also no difference in its expression at 6 and 12 hours (Fig. 7) . Since our results show that CYP26B1 is much more highly expressed than CYP26A1 in the neonatal rat lung, even in the basal state before treatment (comparison not shown), CYP26B1 might plays the major role in metabolizing RA in the neonatal lung. However, CYP26A1 mRNA in the liver was significantly increased by at-RA (data not shown), which suggests its importance in VA metabolism in the neonatal liver and in clearance of VA from the body through biliary excretion of polar retinoid metabolites. Based on these findings, we speculate that LRAT and CYP26B1 are the critical genes in regulating neonatal lung VA homeostasis. Figure 8 suggests how RA and Am580 act both similarly early on and in a differential manner after 12 hours to affect lung RE content and retinoid homeostasis in the lungs. We also determined the expression of several other genes that could potentially contribute to retinol uptake and metabolism was also measured in our study, including the LDL-receptor-related protein (LrP) and lipoprotein lipase (LPL), which might influence the binding and uptake of chylomicron RE, respectively, and the cellular retinol-binding protein, CRBP1, a chaperone protein that delivers retinol to LRAT. However, while the mRNA for each of these genes was readily detected in neonatal lung, expression levels did not change with our treatments. Previous studies showed that CRBP1 in liver was not always saturated with retinol (56), and thus, if this is the case in the lungs, there may be sufficient capacity for binding and metabolizing retinol after VARA treatment, without an increase in CRBP1 expression. Thus, overall, STRA6, LRAT and CYP26B1 appear to be the key 22 retinoid-regulated genes guiding retinoid homeostasis in the neonatal lung.
We also compared the metabolism of newly absorbed Only groups that received VA differed (mean increase for all groups that received VA = 0.49 µmol/L compared to groups that did not receive VA, P <0.001). Relative Lung CYP26A1 mRNA .jlr.org Fig. 8 
